Innovative Technology Infraredx's advanced intravascular imaging systems, including the Makoto system and Dualpro IVUS+NIRS catheter, offer precise mapping of coronary artery disease, enabling healthcare providers to identify high-risk plaques and improve patient outcomes, presenting significant opportunities for sales and distribution in interventional cardiology.

Market Expansion The company's successful launch of the Makoto system in Japan and recent product introductions in the US demonstrate a strategic push into key international markets, opening avenues for sales growth and partnerships with hospitals and medical device distributors globally.

Sustainable Growth With a solid funding base of $25 million and revenue estimates between $10 million to $25 million, Infraredx is positioned for scalable growth, making it an appealing partner for clinics and hospitals seeking innovative diagnostic tools to stay competitive.

Strategic Collaborations Partnerships with industry players like B. Braun Interventional Systems highlight opportunities for co-marketing and joint clinical trials, which can be leveraged to expand product adoption and reach critical decision-makers in cardiology interventions.

Regulatory Milestones Infraredx’s FDA clearance of their imaging systems and ongoing clinical trials provide a strong foundation for sales pitches focused on regulatory compliance and proven efficacy, easing procurement decisions by healthcare providers.